keine Finanzberatung

GILD · Gilead Sciences, Inc.

HIV-franchise pharma; twice-yearly lenacapavir prevention launch

Risiko 4/10 · MODERATE RISK · HIV franchise pharma · $151.00 ▼ 0.15%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $151.00
  • Market cap $187.2B
  • P/E (ttm) n/a
  • Div yield 2.17%
  • 52-wk range $108.46 – $157.29
  • Index rank #77 / #27

Wichtigste Risiken

  • Lenacapavir launch stalling on payer and access pushback (Shareholders) — MED
  • HIV franchise patent erosion later in the decade (Shareholders) — MED
  • Oncology pipeline failing to become the second leg (Shareholders) — MED
  • Drug-pricing politics targeting HIV list prices (Shareholders) — MED

Fazit

A defensive pharma that finally found a new growth leg — the run has claimed the easy money, but the base business is solid.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.